William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker selection trials may help identify in prostate cancer patients.
Advertisement
By Editor
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker selection trials may help identify in prostate cancer patients.